TNFSF11 and neoplasm: Pharmacological inhibition of RANKL in BRCA1-deficient mouse models using the RANKL inhibitor OPG-Fc or a RANKL-specific monoclonal antibody significantly delayed tumor onset, confirming the therapeutic value of targeting the RANKL/RANK pathway to prevent breast oncogenesis in carriers of BRCA1 mutations [2].